Evaluating omadacycline dosing regimens against drug-resistant pathogens including < em > Staphylococcus aureus < /em > , < em > Streptococcus pneumoniae < /em > and < em > Haemophilus influenzae < /em > in adults: a pharmacokinetic/pharmacodynamic analysis using Monte Carlo simulation

In conclusion, approved oral/intravenous loading and maintenance doses of omadacycline showed enough efficacy in the treatment of ABSSI and CABP caused by the main drug-resistant pathogens.PMID:38591989 | DOI:10.1080/1120009X.2024.2339706

Source: Journal of Chemotherapy - April 9, 2024 Category: Cancer & Oncology Authors: Xiao-Chen Wei Ming-Feng Zhao Xia Xiao Source Type: research